S13 Table. Cox proportional hazards model of survival for patients with and without statin exposure before the diagnosis of ER-negative breast cancer

Variable	Univariable analysis Hazard ratio (95% CI)	p-value	Multivariable analysis Hazard ratio (95% CI)	p-value
Histologic type				
IDC	1		1	
ILC	2.607 (1.158-5.870)	0.021	2.478 (1.075-5.711)	0.033
Others	0.305 (0.166-0.558)	< 0.001	0.686 (0.341-1.379)	0.290
Stage: T				
T1	1		1	
T0	1.615 (0.221-11.785)	0.636	1.714 (0.232-12.637)	0.597
T2	3.007 (2.074-4.360)	< 0.001	2.115 (1.436-3.115)	< 0.001
T3	8.214 (5.286-12.764)	< 0.001	3.263 (1.984-5.365)	< 0.001
T4	13.389 (7.866-22.789)	< 0.001	3.781 (2.068-6.910)	< 0.001
Tis	0.353 (0.109-1.145)	0.083	0.661 (0.175-2.501)	0.542
Stage: N				
N0	1		1	
N1	2.222 (1.547-3.192)	< 0.001	1.487 (1.021-2.167)	0.039
N2	6.537 (4.603-9.283)	< 0.001	3.610 (2.452-5.313)	< 0.001
N3	9.339 (6.523-13.370)	< 0.001	4.333 (2.837-6.619)	< 0.001
Stage: M				
M0	1		1	
M1	6.911 (3.945-12.108)	< 0.001	2.287 (1.265-4.135)	0.006
PR				
Negative	1		1	
Positive	0.433 (0.178-1.050)	0.064	0.630 (0.258-1.541)	0.311

Age at diagnosis (yr)				
< 40	1		1	
≥ 40 and < 50	0.531 (0.365-0.774)	0.001	0.611 (0.414-0.902)	0.013
≥ 50	0.560 (0.408-0.769)	< 0.001	0.655 (0.465-0.923)	0.016
CCI	1.116 (1.052-1.185)	< 0.001	1.078 (1.011-1.151)	0.023
Exposure to statin				
No	1		1	
Yes	0.969 (0.591-1.591)	0.903	0.987 (0.648-1.503)	0.951

CCI, Charlson comorbidity index; CI, confidence interval; ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; M, metastasis; N, node; PR, progesterone receptor; T, tumor.